IDEAS home Printed from https://ideas.repec.org/f/pma997.html
   My authors  Follow this author

Jörg C. Mahlich

Personal Details

First Name:Jörg
Middle Name:C.
Last Name:Mahlich
Suffix:
RePEc Short-ID:pma997
http://www.xing.com/profile/Joerg_Mahlich

Affiliation

Institut für Volkswirtschaftslehre
Fakultät für Wirtschaftswissenschaften
Universität Wien

Wien, Austria
http://econ.univie.ac.at/

: [+43] 1-4277-37401
[+43] 1-4277-9374
Oskar-Morgenstern-Platz 1, A-1090 Vienna
RePEc:edi:wiwuwat (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
  2. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," MERIT Working Papers 015, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
  3. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2001. "The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?," Research Memorandum 001, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).

Articles

  1. Jörg Mahlich & Shinichiro Okamoto & Akiko Tsubota, 2017. "Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib," PharmacoEconomics - Open, Springer, vol. 1(3), pages 195-202, September.
  2. Mona Groß & Annika Herr & Martin Hower & Alexander Kuhlmann & Jörg Mahlich & Matthias Stoll, 2016. "Unemployment, health, and education of HIV-infected males in Germany," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 61(5), pages 593-602, June.
  3. Philipp Hafner & Jörg C. Mahlich, 2016. "Determinants of physician's office visits and potential effects of co-payments: evidence from Austria," International Journal of Health Planning and Management, Wiley Blackwell, vol. 31(3), pages 192-203, July.
  4. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
  5. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
  6. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 509-521, October.
  7. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 689-689, December.
  8. Axel Mühlbacher & Matthias Stoll & Jörg Mahlich & Matthias Nübling, 2013. "Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment," Health Economics Review, Springer, vol. 3(1), pages 1-11, December.
  9. Hans Dimai & Kurt Redlich & Monika Peretz & Fredrik Borgström & Uwe Siebert & Jörg Mahlich, 2012. "Economic burden of osteoporotic fractures in Austria," Health Economics Review, Springer, vol. 2(1), pages 1-10, December.
  10. Jörg Mahlich, 2011. "R&D Management Of Japanese Pharmaceutical Firms," International Journal of Innovation and Technology Management (IJITM), World Scientific Publishing Co. Pte. Ltd., vol. 8(02), pages 211-226.
  11. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.
  12. Jörg Mahlich & Thomas Roediger-Schluga, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 145-164, March.
  13. Mahlich Jörg, 2005. "Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie," Zeitschrift für Wirtschaftspolitik, De Gruyter, vol. 54(3), pages 366-390, December.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," MERIT Working Papers 015, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).

    Cited by:

    1. Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
    2. Desiderio Romero-Jordán & María Delgado-Rodríguez & Inmaculada Álvarez-Ayuso & Sonia Lucas-Santos, 2014. "Assessment of the public tools used to promote R&D investment in Spanish SMEs," Small Business Economics, Springer, vol. 43(4), pages 959-976, December.
    3. Civan Abdulkadir & Maloney Michael T., 2009. "The Effect of Price on Pharmaceutical R&D," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 9(1), pages 1-24, April.
    4. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
    5. Evens Salies, 2010. "A Test of the Schumpeterian Hypothesis in a Panel of European Electric Utilities," Chapters,in: Innovation, Economic Growth and the Firm, chapter 6 Edward Elgar Publishing.
    6. Shilpi Tyagi & D. K. Nauriyal & Rachita Gulati, 2018. "Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry," Review of Managerial Science, Springer, vol. 12(1), pages 167-202, January.
    7. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.

  2. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2001. "The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?," Research Memorandum 001, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).

    Cited by:

    1. Patrick Cohendet & Matthieu Farcot & Julien Pénin, 2009. "Intellectual property in a knowledge-based economy : Patents to include vs. patents to exclude," Working Papers of BETA 2009-15, Bureau d'Economie Théorique et Appliquée, UDS, Strasbourg.

Articles

  1. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 509-521, October.

    Cited by:

    1. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.

  2. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 689-689, December.

    Cited by:

    1. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.

  3. Hans Dimai & Kurt Redlich & Monika Peretz & Fredrik Borgström & Uwe Siebert & Jörg Mahlich, 2012. "Economic burden of osteoporotic fractures in Austria," Health Economics Review, Springer, vol. 2(1), pages 1-10, December.

    Cited by:

    1. Hans Concin & Wolfgang Brozek & Karl-Peter Benedetto & Hartmut Häfele & Joachim Kopf & Thomas Bärenzung & Richard Schnetzer & Christian Schenk & Elmar Stimpfl & Ursula Waheed-Hutter & Hanno Ulmer & Ki, 2016. "Hip fracture incidence 2003–2013 and projected cases until 2050 in Austria: a population-based study," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 61(9), pages 1021-1030, December.

  4. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.

    Cited by:

    1. Patricia Laurens & Christian Le Bas & Antoine Schoen, 2018. "Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter?," Post-Print hal-01725229, HAL.
    2. Lechevalier, Sébastien & Nishimura, Junichi & Storz, Cornelia, 2014. "Diversity in patterns of industry evolution: How an intrapreneurial regime contributed to the emergence of the service robot industry," Research Policy, Elsevier, vol. 43(10), pages 1716-1729.
    3. Xiaoqing Li & Yu Zheng & Catherine L. Wang, 2016. "Inter-firm collaboration in new product development in Chinese pharmaceutical companies," Asia Pacific Journal of Management, Springer, vol. 33(1), pages 165-193, March.

  5. Jörg Mahlich & Thomas Roediger-Schluga, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 145-164, March.
    See citations under working paper version above.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 1 paper announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-GER: German Papers (1) 2014-05-24
  2. NEP-HEA: Health Economics (1) 2006-05-27
  3. NEP-INO: Innovation (1) 2006-05-27
  4. NEP-SEA: South East Asia (1) 2006-05-27
  5. NEP-TID: Technology & Industrial Dynamics (1) 2006-05-27

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Jörg C. Mahlich should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.